Magnesium I.V. Verla

Magnesium sulfate, the active ingredient in Magnesium I.V. Verla, is a magnesium salt / electrolyte presented as an intravenous solution for intravenous use. It is employed to correct magnesium deficiency, prevent and treat eclampsia or preeclampsia, manage certain cardiac arrhythmias such as torsades de pointes, and serve as an adjunct in severe asthma exacerbations.

GNH USA supplies Magnesium I.V. Verla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring consistent quality and regulatory compliance.

Magnesium I.V. Verla provides magnesium ions to address electrolyte disturbances and related clinical conditions.

Magnesium deficiency: restores normal serum magnesium levels and supports enzymatic functions. Eclampsia / preeclampsia: prevents seizures and stabilizes blood pressure in pregnant patients at risk. Torsades de pointes and other cardiac arrhythmias: helps terminate ventricular tachyarrhythmias by antagonizing calcium influx. Severe asthma exacerbations: acts as a bronchodilator adjunct to improve airway smooth‑muscle relaxation.

Magnesium I.V. Verla may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Flushing or feeling of warmth: transient sensation during infusion. - Nausea: mild gastrointestinal upset. - Hypotension: drop in blood pressure, especially with rapid administration.

Serious or Rare Side Effects: - Hypermagnesemia: elevated serum magnesium causing muscle weakness or cardiac effects. - Cardiac arrest: severe conduction disturbances leading to loss of cardiac output. - Respiratory depression: reduced respiratory drive in high concentrations.

When using Magnesium I.V. Verla, clinicians should consider several safety measures.

Renal impairment: monitor serum magnesium and adjust infusion rate. Cardiac disease: observe for bradycardia or heart block. Neuromuscular disorders: use cautiously due to risk of muscle weakness. Pregnancy: administer only when benefit outweighs potential risk to fetus. Concomitant medications: review drugs that affect magnesium levels. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magnesium I.V. Verla can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Calcium channel blockers: additive hypotensive effect. - Neuromuscular blocking agents: potentiation of muscle relaxation. - Other magnesium‑containing products: risk of hypermagnesemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal magnesium loss, may require dose adjustment. - ACE inhibitors or ARBs: alter renal handling of magnesium, monitor levels.